In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

In a test for AI, buzzy startup Insitro inks drug discovery deal with Gilead

In a test for AI, a buzzy machine learning startup inks drug discovery deal with Gilead

By MATTHEW HERPER AND REBECCA ROBBINS

NEILSON BARNARD/GETTY IMAGES FOR THE NEW YORK TIMES

It is the company’s first deal with a drug maker, and offers a test of whether artificial intelligence can remake drug development.

READ MORE